JP2022510690A5 - - Google Patents
Info
- Publication number
- JP2022510690A5 JP2022510690A5 JP2021532071A JP2021532071A JP2022510690A5 JP 2022510690 A5 JP2022510690 A5 JP 2022510690A5 JP 2021532071 A JP2021532071 A JP 2021532071A JP 2021532071 A JP2021532071 A JP 2021532071A JP 2022510690 A5 JP2022510690 A5 JP 2022510690A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- aryl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199809A JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775799P | 2018-12-05 | 2018-12-05 | |
| US62/775,799 | 2018-12-05 | ||
| US201962821303P | 2019-03-20 | 2019-03-20 | |
| US62/821,303 | 2019-03-20 | ||
| PCT/US2019/064548 WO2020117987A1 (en) | 2018-12-05 | 2019-12-04 | Compositions and methods for the treatment of liver disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199809A Division JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510690A JP2022510690A (ja) | 2022-01-27 |
| JP2022510690A5 true JP2022510690A5 (cg-RX-API-DMAC7.html) | 2022-12-13 |
Family
ID=70974003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532071A Pending JP2022510690A (ja) | 2018-12-05 | 2019-12-04 | 肝障害の処置のための組成物及び方法 |
| JP2024199809A Pending JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199809A Pending JP2025028061A (ja) | 2018-12-05 | 2024-11-15 | 肝障害の処置のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220016136A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3890748A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022510690A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210099612A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113365637A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019394947B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021010916A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3121620A1 (cg-RX-API-DMAC7.html) |
| MX (5) | MX2021006575A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020117987A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| CN115093404B (zh) * | 2020-07-17 | 2024-06-21 | 瀚海新拓(杭州)生物医药有限公司 | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2025193816A1 (en) * | 2024-03-14 | 2025-09-18 | Viking Therapeutics, Inc. | Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428516A1 (en) * | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| US20090232879A1 (en) * | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| MX2011011376A (es) * | 2009-04-27 | 2012-04-20 | Immuron Ltd | Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| CA2871793C (en) * | 2012-05-02 | 2020-09-15 | Pharmaxis Ltd. | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| AU2018280118B2 (en) * | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EP4161925A4 (en) * | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
-
2019
- 2019-12-04 EP EP19893549.6A patent/EP3890748A4/en active Pending
- 2019-12-04 JP JP2021532071A patent/JP2022510690A/ja active Pending
- 2019-12-04 AU AU2019394947A patent/AU2019394947B2/en active Active
- 2019-12-04 CA CA3121620A patent/CA3121620A1/en active Pending
- 2019-12-04 BR BR112021010916-1A patent/BR112021010916A2/pt unknown
- 2019-12-04 MX MX2021006575A patent/MX2021006575A/es unknown
- 2019-12-04 WO PCT/US2019/064548 patent/WO2020117987A1/en not_active Ceased
- 2019-12-04 US US17/311,014 patent/US20220016136A1/en active Pending
- 2019-12-04 CN CN201980091024.3A patent/CN113365637A/zh active Pending
- 2019-12-04 KR KR1020217020331A patent/KR20210099612A/ko active Pending
-
2021
- 2021-06-03 MX MX2024001204A patent/MX2024001204A/es unknown
- 2021-06-03 MX MX2024001203A patent/MX2024001203A/es unknown
- 2021-06-03 MX MX2024001205A patent/MX2024001205A/es unknown
- 2021-06-03 MX MX2024001201A patent/MX2024001201A/es unknown
-
2024
- 2024-11-15 JP JP2024199809A patent/JP2025028061A/ja active Pending
-
2025
- 2025-08-22 AU AU2025220854A patent/AU2025220854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7604666B2 (ja) | 代謝及び肝臓障害の処置のための組成物及び方法 | |
| ES2836973T3 (es) | Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes | |
| RU2569063C2 (ru) | Конъюгаты жирных кислот и ниацина и их применение | |
| ES2525429T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| ES2397664T3 (es) | Derivados de glucopiranósilo que contienen tienilo como antidiabéticos | |
| US20130190327A1 (en) | Bis-fatty acid conjugates and their uses | |
| WO2009038204A1 (ja) | 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするgタンパク質共役型レセプター作動剤 | |
| RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
| RU2003110577A (ru) | Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами | |
| EA021174B1 (ru) | Применение ингибиторов дипептидилпептидазы | |
| KR20110013411A (ko) | (f-19)-표지된 l-글루탐산 및 l-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법 | |
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| US20090074844A1 (en) | Trenadermal absorption preparation | |
| KR20250041009A (ko) | 대사 및 간 장애 치료를 위한 조성물 및 방법 | |
| JP5014978B2 (ja) | ヘテロ6員環化合物及びその用途 | |
| ES2202449T3 (es) | Inhibidor de edema cerebral. | |
| JP7812338B2 (ja) | Glp受容体アゴニスト | |
| TW202412761A (zh) | 以ask1抑制劑治療器官疾病或病症的方法 | |
| US20040152753A1 (en) | Methods of use for novel sulfur containing organic nitrate compounds | |
| JP2008530242A5 (cg-RX-API-DMAC7.html) | ||
| JP7661969B2 (ja) | 1,4,5,6-テトラヒドロピリミジン-2-アミン誘導体 | |
| JP2023553989A5 (cg-RX-API-DMAC7.html) | ||
| ES2890924T3 (es) | Derivados de imidazol para el tratamiento de la hipertensión y/o la fibrosis | |
| JP2009513606A (ja) | β−3受容体アゴニストとして使うためのベンゾイミダゾール誘導体 | |
| RU2025110010A (ru) | Фармацевтическая композиция двойного агониста рецепторов glp-1 и gip и ее применение |